BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab-MedSci.cn

BMI impact on the prognosis of unresectable HCC patients receiving first-line lenvatinib or atezolizumab plus bevacizumab

Amadeo, E; Persano, M; Tada, T; Suda, G; Shimose, S; Kudo, M; Yoo, C; Rossari, F; Vitiello, F; Gardini, AC; Rimini, M

ANNALS OF ONCOLOGY, 2023; 34 (): S1539

科室
- - 订阅+
  - 更多科室
工具
服务